Pharmasset Inc. (VRUS) filed Quarterly Report for the period ended 2009-06-30.

PHARMASSET INC is a clinical-stage pharmaceutical company committed to discovering developing and commercializing novel drugs to treat viral infections. Pharmasset\'s primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus hepatitis C virusand human immunodeficiency virus. Pharmasset Inc. has a market cap of $415.21 million; its shares were traded at around $14.77 with and P/S ratio of 223.59.

Highlight of Business Operations:

At least six major genotypes of HCV have been identified, each with multiple subtypes. Genotypes are designated with numbers (genotypes 1-6) and subtypes with letters. HCV genotypes 1, 2, and 3 appear to have a worldwide distribution, but their prevalence varies from one geographic area to another. Genotype 1 and its subtypes (1a and 1b) are the most common genotype globally, accounting for approximately 70% of infections. Patients with genotype 2 or 3 represent approximately 25% of the worldwide chronically infected HCV population and the remaining 5% is comprised of genotypes 4 through 6. Worldwide sales of HCV drugs in 2005 were approximately $2.2 billion and are forecasted to reach more than $8.0 billion in 2015. Historical sales of HCV drugs increased as new therapies were introduced that improved the sustained viral response, or SVR, defined as the inability to detect HCV RNA in a patient’s blood six months after discontinuation of therapy, with a standard test utilizing polymerase chain reaction, or PCR.

All of our product candidates are currently in development, and, therefore, we do not expect to generate any direct revenues from drug product sales for at least the next several years, if at all. Our revenues to date have been generated primarily from milestone payments under our collaboration agreements, license fees, and research funding. We currently have one collaboration agreement with Roche for the development of PSI-6130 and its pro-drugs. We entered into our collaboration agreement with Roche in October 2004. Roche subsequently paid us an up-front payment of $8.0 million. Pursuant to the terms of our collaboration agreement with Roche, we received a $10.0 million milestone payment during the quarter ended June 30, 2009. As of June 30, 2009, we had received an aggregate of $44.4 million in payments under the Roche collaboration agreement, including research and development payments, as well as up-front license and milestone payments. Under the current terms of the Roche collaboration agreement, if we succeed in obtaining all of the regulatory approvals specified in the agreement for PSI-6130 or a pro-drug of PSI-6130, including RG7128, as of June 30, 2009, the maximum future development and commercialization milestone payments payable to us are $105.0 million. Receipt of any additional milestone payments depends on many factors, some of which are beyond our control. We cannot assure you that we will receive any of these future payments.

Read the The complete Report